Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008

Oslo University Hospital60 enrolled

Overview

The study will examine the prevalence of venous thromboembolism in children with acute lymphoblastic leukaemia treated in accordance with NOPHO ALL-2008. The investigators will prospectively study clinical symptomatic thromboses, asymptomatic central line-associated thromboses, and infections.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Thromboembolism Acute Lymphoblastic Leukemia

Eligibility

Sex: ALLMin age: 1 YearMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Acute lymphoblastic leukaemia, * Age 1 year to 16 years old, * Central line, * Protocol NOPHO ALL 2008. Exclusion Criteria: * Refusal of participation, * Treated according to protocol other than NOPHO ALL 2008.

Locations (1)

Rikshospitalet, Dep of Pediatrics

Oslo, Oslo, Norway

RECRUITING

Outcomes

Primary Outcomes

Clinical evident thrombosis

Time frame: 33 weeks

Asymptomatic central line-associated thrombosis

Time frame: 33 weeks

Secondary Outcomes

Positive blood culture

Time frame: 33 weeks

Central Contacts

Ellen Ruud, MD PhD

CONTACT

+47 23074560 ellen.ruud@rikshospitalet.no

Tonje Reiersen, MD

CONTACT

+47 23070000 tonje.reiersen@rikshospitalet.no

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.